NFS-02 (rAAV2-ND1)
Leber's Hereditary Optic Neuropathy (LHON) due to ND1 mutation
Phase 1/2IND approved in China, FDA Orphan Drug Designation
Key Facts
Indication
Leber's Hereditary Optic Neuropathy (LHON) due to ND1 mutation
Phase
Phase 1/2
Status
IND approved in China, FDA Orphan Drug Designation
Company
About Neurophth Therapeutics
China's leading ocular gene therapy company developing AAV-based treatments for inherited retinal diseases like LHON.
View full company profile